Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by GSK Canada
Canada approves first functional-cure therapy for hepatitis B
Health Canada approved Hibsago, the first finite functional-cure therapy for chronic hepatitis B, but eligibility, cost and durability will limit its reach. SN How Streamline reports this story Build your reading streak0/3 today·Counts at 25% No sign-in required. Choose up to two. This captures your response to the story—it is not a vote on whether the reporting is true. 7 source references Sources linked in this article’s evidence ledger.
Hibsago (bepirovirsen) Approved in Canada as the First and Only Finite Therapy Indicated to Achieve Functional Cure of Chronic Hepatitis B
Member News November 3, 2026 GSK Canada MISSISSAUGA, ON – GSK announced that Health Canada has approved Hibsago (bepirovirsen) as a finite treatment to achieve functional cure of chronic hepatitis B (CHB) virus infection in non-cirrhotic adult patients who have been on nucleos(t)ide analogue therapy for at least 6 months and with HBV DNA <90 IU/mL, and have hepatitis B surface antigen (HBsAg) levels ≤3,000 IU/mL.
GSK Canada and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Blenrep for the Treatment of Relapsed or Refractory Multiple Myeloma
Member News September 22, 2026 GSK Canada Mississauga, ON – GSK Canada announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), resulting in a Letter of Intent (LOI) for Blenrep (belantamab mafodotin for injection) for the treatment of adult patients with relapsed or refractory multiple myeloma. The LOI with the pCPA is an important step towards securing public drug plan coverage for Blenrep across Canada.
Nucala (mepolizumab) receives a positive reimbursement recommendation from CDA-AMC for adults with chronic obstructive pulmonary disease (COPD)
Member News August 18, 2026 GSK Canada Canada’s Drug Agency (CDA-AMC) affirms the value of Nucala for adults with COPD characterized by raised blood eosinophils. This recommendation is a significant step toward securing public funding for eligible patients in Canada, with provincial and territorial governments making the final decision on public coverage.
New poll reveals Ontarians’ overwhelming desire for government investment in preventive healthcare measures
Member News August 5, 2026 GSK Canada Findings point to an opportunity to expand access to adult vaccination, support healthy aging and help build a more resilient healthcare system Recognition for growing evidence of the economic benefits of adult vaccination Mississauga, ON – As Ontario’s healthcare system faces increasing pressure from an aging population, new polling by Leger conducted on behalf of GSK reveals that Ontarians overwhelmingly support a prevention-first approach to healthcare.
New survey reveals Canadians underestimate chronic hepatitis B and its link to liver cancer
Member News July 28, 2026 GSK Canada Nearly 9 in 10 Canadians have little to no awareness of chronic hepatitis B (CHB) Only 31% rank CHB as a high cancer risk, revealing a significant gap between perception and reality Just 14% report to have been tested for CHB, yet CHB causes 56%2 of liver cancer cases and affects over 262,000 in Canada3 MISSISSAUGA, ON – GSK released new data insights from a global survey marking World Hepatitis Day.
Exdensur (depemokimab injection) approved in Canada for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps
Member News June 16, 2026 GSK Canada Exdensur is the first and only long-acting biologic with twice-yearly dosing approved in Canada for severe asthma characterized by an eosinophilic phenotype and chronic rhinosinusitis with nasal polyps (CRSwNP). In Canada, approximately half of people living with asthma remain uncontrolled, with asthma attacks leading to more than 80,000 emergency room visits annually, while an estimated hundreds of thousands are affected by CRSwNP.
Nucala (mepolizumab) approved in Canada for Use in Adults with Chronic Obstructive Pulmonary Disease (COPD)
Member News June 9, 2026 GSK Canada Nucala is the only approved biologic showing efficacy for up to two years in a wide spectrum of COPD patients with raised blood eosinophils inadequately controlled by the combination of an ICS/LABA/LAMA. Approval is based on MATINEE, METREX and METREO Phase III trials. MATINEE data showed a reduction in moderate/severe exacerbations, including those leading to hospitalization and/or emergency department visits.
GSK and the pan-Canadian Pharmaceutical Alliance (pCPA) initiate negotiations for Blenrep for the treatment of relapsed or refractory multiple myeloma - Life Sciences British Columbia
Member News May 20, 2026 GSK Canada This is another key milestone in offering relapsed and refractory multiple myeloma patients a treatment featuring a differentiated mode of action.
GSK Canada Secures Priority review for Regulatory Submission of Bepirovirsen, a Potential Functional Cure Treatment for Chronic hHpatitis B
Member News April 30, 2026 GSK Canada The new drug submission for bepirovirsen was granted priority review, underscoring the unmet need for patients Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well trials An estimated 262,000 people in Canada live with chronic hepatitis B, a leading cause of liver cancer1 MISSISSAUGA, ON — GSK announced that it has filed a new drug submission for bepirovirsen for regulatory review in...
GSK Enters Agreement to Acquire 35Pharma Inc.
Member News February 25, 2026 GSK Canada Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary hypertension (PH) patients while reducing the risk of bleeding and providing unique metabolic benefits compared to existing therapies HS235’s profile bolsters an emerging pipeline of products with protective benefits on metabolic and vascular function, providing...
Survey Finds Majority of Older Canadians with Chronic Illnesses Unaware of Increased Shingles Risk
Member News February 23, 2026 GSK Canada Over half of respondents (55%) are unsure or do not know that their chronic health condition may increase their risk of developing shingles Majority (77%) fear disruption to daily life from shingles, yet nearly half (46%) say they have never discussed shingles with a healthcare professional (HCP) Survey data highlights need for more informed and proactive conversations about shingles with HCPs MISSISSAUGA, ON – In Canada, shingles affects an estimated...
Quebec First Province to Publicly Reimburse Jemperli (dostarlimab for injection) plus Chemotherapy via RAMQ for the Treatment of all Adult Patients with Primary Advanced or First Recurrent Endometrial Cancer - Life Sciences British Columbia
Member News February 3, 2026 GSK Canada First province in Canada to publicly reimburse this expanded indication of Jemperli, marking a significant milestone in access to treatment. This listing removes a key financial barrier for eligible Quebecers, enabling timely access to this standard-of-care combination therapy.
GSK and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Finalize Negotiations for JEMPERLI plus Chemotherapy for all Adult Patients with Primary Advanced or first Recurrent Endometrial Cancer - Life Sciences British Columbia
Member News December 4, 2025 GSK Canada This milestone is a key step toward public reimbursement; decisions now rest with provincial and territorial governments to ensure patients can benefit from this important treatment.
GSK Survey Highlights Gaps in RSV Awareness, Risk Understanding Among Vulnerable Older Canadian Adults
Member News November 5, 2025 GSK Canada Many Canadian adults aged 50+ with certain chronic health conditions underestimate their personal risk of severe RSV illness despite a higher chance of serious illness and hospitalization.2,3,4,5 Responses also show many Canadians at a higher risk of severe RSV illness are not discussing the virus with their doctor and most have not received the RSV vaccination.
New Study Highlights Concerning Link Between Heart Disease and Shingles Risk
Member News October 23, 2025 GSK Canada Findings reveal a 15% elevated risk of shingles among adults with cardiovascular disease Results show the risk of shingles increased up to 27% among adults with two or more chronic conditions compared to those without such health issues MISSISSAUGA, ON – Results from a new retrospective study (VEO-000477) adds to research uncovering a relationship between cardiovascular disease (CVD) and herpes zoster, commonly referred to as shingles.
GSK’s $300,000 Investment Fuels Launch of Innovative Lung Wellness Clinic to Transform Respiratory Care in Nova Scotia
Member News October 21, 2025 GSK Canada MISSISSAUGA ON – Dalhousie University, in collaboration with Nova Scotia Health’s INSPIRED COPD Outreach Program, the Nova Scotia Health Innovation Hub and the LungNSPEI, is proud to announce the upcoming launch of the Nova Scotia Lung Wellness Clinic, a groundbreaking initiative designed to address urgent respiratory health challenges and improve outcomes for Nova Scotians.
GSK Begins Shipping Influenza Vaccine Doses for the 2025-26 Flu Season in Canada
Member News September 8, 2025 GSK Canada GSK supports seasonal flu immunization in Canada with domestic supply of Fluviral vaccine in advance of flu season MISSISSAUGA, ON – GSK Canada (GlaxoSmithKline Inc.) announced it has started shipping doses of its trivalent seasonal influenza vaccine, Fluviral, to Canadian provinces in preparation for the 2025-26 flu season.
New Real-world Study Reveals Oral Corticosteroid Overuse in Patients with Chronic Rhinosinusitis with Nasal Polyps
Member News June 10, 2025 GSK Canada According to the ACTIONS study, 39% of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) faced overexposure to oral corticosteroids (OCS) before beginning biologic therapy. ACTIONS was carried out by GSK in collaboration with Asthma Canada and leading Canadian Rhinologists.
GSK’s Depemokimab Accepted for Review by Health Canada for the Treatment of Asthma with Type 2 Inflammation and for Chronic Rhinosinusitis with Nasal Polyps - Life Sciences British Columbia
Member News May 26, 2025 GSK Canada SWIFT-1 and -2 trials showed depemokimab reduced exacerbation and hospitalization rates as an add-on therapy for patients with asthma with type 2 inflammation versus placebo ANCHOR-1 and -2 trials showed early and sustained reductions in nasal polyp size and nasal obstruction versus placebo for patients with chronic rhinosinusitis with nasal polyps Across the SWIFT and ANCHOR clinical trials, the overall incidence and severity of treatment-emergent adverse...
GSK’s Nucala (mepolizumab) Accepted for Review by Health Canada for the Treatment of COPD
Member News February 26, 2025 GSK Canada Submission supported by MATINEE data showing significant and clinically meaningful reduction in annualized rate of moderate/severe exacerbations compared with placebo MISSISSAUGA, ON – GSK has submitted a Supplementary New Drug Submission (SNDS) to Health Canada to expand the use of Nucala (mepolizumab) to include add-on maintenance treatment for adult patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.
National Survey Reveals Low Understanding of Shingles Risk Factors and Lack of Concern Among Those at Increased Risk
Member News February 25, 2025 GSK Canada Only one-third (34%) of respondents believe that a chronic health condition such as diabetes, asthma or heart disease can increase one’s risk of getting shingles Among those with a chronic condition, concern of getting shingles is low with only 12% highly concerned and 37% somewhat concerned Over 80% of those with a chronic condition have not been informed by a healthcare professional about an increased risk for shingles MISSISSAUGA, ON – A new...
Canada’s Drug Agency Recommends OJJAARA for Public Reimbursement
Member News February 13, 2025 GSK Canada Ojjaara received a reimburse recommendation from Canada’s Drug Agency, a decisive achievement in advancing access to rare blood cancer treatments. MISSISSAUGA, ON – Ojjaara (momelotinib) has received a reimburse with conditions recommendation from Canada’s Drug Agency (CDA-AMC). The recommendation is an important milestone towards securing public reimbursement, following Ojjaara’s approval from Health Canada in November 2024.
Comment une femme a trouvé sa force à travers son parcours contre le cancer de l'ovaire
Peggy Pickett espère sensibiliser les femmes à la nécessité d’une détection précoce, à l’importance de défendre leurs intérêts et à la valeur du soutien de la communauté des patientes. Créé par Peggy Pickett, 57 ans, menait une vie remplie et active : elle adorait son travail à temps plein, elle voyageait, faisait du bénévolat, tricotait, jouait de la guitare et passait du temps en famille. Au début de 2012, elle a commencé à sentir une étrange douleur dans le haut de son flanc droit.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with GSK
Contact GSK, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack